Promegestone

Promegestone (INN) (brand name Surgestone), also known as 17α,21-dimethyl-19-nor-Δ⁴,⁹-pregnadiene-3,20-dione, is a 19-norprogesterone derivative and steroidal progestin which was introduced in 1983 and is marketed in France, Portugal, and Argentina.^[1]^[2]^[3]^[4] Indications include gynaecological conditions caused by luteal insufficiency, including premenopausal disorders, dysmenorrhea, and premenstrual syndrome.^[4] Unlike some other progestins, promegestone is devoid of androgenic properties.^[4]

In addition to its progestogenic properties, promegestone has also been found to act as a non-competitive antagonist of the nicotinic acetylcholine receptor.^[5]

References

↑ R.A. Hill; H.L.J. Makin; D.N. Kirk (23 May 1991). Dictionary of Steroids. CRC Press. pp. 759–. ISBN 978-0-412-27060-4. Unknown parameter |coauthors= ignored (help)
↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 883–. ISBN 978-3-88763-075-1.
↑ ^4.0 ^4.1 ^4.2 Cain (11 September 1984). ANNUAL REPORTS IN MED CHEMISTRY V19 PPR. Academic Press. pp. 323–. ISBN 978-0-08-058363-1.
↑ Blanton MP, Xie Y, Dangott LJ, Cohen JB (February 1999). “The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface”. Mol. Pharmacol. 55 (2): 269–78. PMID 9927618.